|Bid||123.43 x 800|
|Ask||123.52 x 1000|
|Day's Range||115.33 - 124.47|
|52 Week Range||91.57 - 135.48|
|Beta (3Y Monthly)||0.80|
|PE Ratio (TTM)||20.74|
|Earnings Date||Oct 24, 2018 - Oct 29, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||138.94|
IQVIA (IQV) delivered earnings and revenue surprises of 2.16% and 0.50%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
The Danbury, Connecticut-based company said it had net income of 29 cents per share. Earnings, adjusted for one-time gains and costs, came to $1.42 per share. The results topped Wall Street expectations. ...
DANBURY, Conn. & RESEARCH TRIANGLE PARK, N.C.-- -- Revenue $2,594 million, up 6.3 percent at constant currency and 5.2 percent reported Adjusted EBITDA $561 million, up 8.4 percent at constant currency and 9.4 percent reported GAAP Diluted Earnings per Share $0.29 Adjusted Diluted Earnings per Share $1.42, up 19.3 percent $792 million of share repurchase completed year-to-date; $133 million during ...
IQVIA today announced that the pharmaceuticals division of Roche has selected IQVIA’s commercial technology suite for deployment across more than 100 markets.
IQVIA Holdings Inc. , will announce its third-quarter 2018 financial results before the market opens on Monday, October 22, 2018. The IQVIA management team will also host a conference call and webcast at 9:00 a.m.
NEW YORK, Oct. 11, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
From Iqvia to Red Hat to Bandwidth, insiders at Triangle companies continued to rake in millions in the third quarter by selling shares, U.S. Securities and Exchange Commission filings show.
IQVIA™ (IQV) and Genomics England today announced a collaboration to develop a platform that will connect clinical and de-identified genomics data to accelerate treatment advancements for patients. Using IQVIA’s E360TM platform, authorized researchers will have privacy-protected, technology-enabled access to Genomics England’s patient-consented, de-identified data to create custom clinical-genomic datasets and run leading-edge analytics on genomics and observable traits. Combining IQVIA’s leading real-world technologies and services experts with Genomics England’s datasets, network and infrastructure to generate, organize, and enhance genomic data, can make the United Kingdom one of the most attractive places for life sciences companies to invest.
IQVIA (IQV) today announced the expansion of its alliance with Salesforce, the global leader in CRM and provider of Software as a Service (SaaS) solutions, to build a clinical solution for life sciences on Salesforce Health Cloud. IQVIA’s suite of clinical technology solutions can speed clinical trials, while reducing patient burden, with the ultimate goal of advancing human health. “We are proud of this strategic collaboration with IQVIA’s technology capabilities and the important role that Salesforce will have in accelerating clinical innovation,” said Tyler Prince, EVP, Industries and Partners, Salesforce.
PerkinElmer is working to ease the drug discovery process for pharmaceutical companies with its suite of research, detection and diagnostics tools.
Moody's Investors Service, ("Moody's") affirmed the ratings of IQVIA Inc., including the Ba2 Corporate Family Rating and Ba2-PD Probability of Default Rating. Moody's also affirmed the Ba1 senior secured credit facility ratings, the Ba3 unsecured notes ratings and the SGL-1 Speculative Grade Liquidity Rating. At the same time, Moody's revised the rating outlook to stable from negative.
Technology partnership with Theramex is likely to boost IQVIA Holdings' (IQV) presence in Europe, Africa and Asia-Pacific regions.
IQVIA Holdings (IQV) serves the life sciences industry with the help of advanced analytics, technology solutions and contract research services.
IQVIA™ (IQV), a company dedicated to applying advanced analytics and technology in healthcare to help clients find better solutions for patients, and Theramex, an international pharmaceutical company dedicated to women’s health, today announced a global technology collaboration to integrate IQVIA’s market-leading Orchestrated Customer Engagement (OCE) platform into Theramex’s European commercial operations.
NEW YORK, Aug. 06, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of IQVIA ...
IQVIA™ today announced that the global biopharmaceutical company Medytox has selected IQVIA’s Enterprise Quality Management Solutions platform for quality and compliance management.
IQVIA (IQV) today announced that Jon Resnick, IQVIA’s president, Real-World & Analytics Solutions, has been named to PharmaVOICE magazine’s annual list of the 100 most influential and inspiring individuals within the life sciences industry. Resnick, who was nominated by John Hervey, CEO of healthcare data and analytics company Cota Inc., has led the transformation of the way real-world evidence is generated and applied using advances such as machine learning, federated platforms, novel methodologies, and SaaS technologies.